We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Adma Biologics Inc | NASDAQ:ADMA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.164 | 2.41% | 6.974 | 6.82 | 6.98 | 6.94 | 6.76 | 6.90 | 2,412,729 | 01:00:00 |
Delaware
|
56-2590442
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
465 State Route 17
|
||
Ramsey, New Jersey
|
07446
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Adam S. Grossman
|
|
|
President and Chief Executive Officer
|
David C. Schwartz, Esq.
|
|
ADMA Biologics, Inc.
|
Morgan, Lewis & Bockius LLP
|
|
465 State Route 17
|
502 Carnegie Center
|
|
Ramsey, New Jersey 07446
|
Princeton, New Jersey 08540
|
|
(201) 478-5552
|
(609) 919 6600
|
|
(Name, address, telephone number,
including area code, of agent for service)
|
(With copies to)
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☒
(Do not check if a smaller reporting company)
|
Smaller reporting company ☒
|
Emerging growth company ☐
|
EXHIBIT
NUMBER
|
DESCRIPTION
|
|
Rights Agreement, dated as of December 20, 2021, by and between ADMA Biologics, Inc. and Continental Stock Transfer and Trust Company, as rights agent (incorporated by reference to Exhibit
4.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 21, 2021).
|
||
Opinion of Morgan, Lewis and Bockius LLP, counsel for the Registrant, regarding the legal validity of the shares of Common Stock being registered on this Registration Statement (filed
herewith).
|
||
Amended and Restated ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Registration Statement on Form S-8
filed on August 18, 2017).
|
||
Consent of Morgan, Lewis and Bockius LLP (contained in Exhibit 5.1).
|
||
Consent of CohnReznick LLP, the Registrant’s Independent Registered Public Accounting Firm (filed herewith).
|
||
Power of Attorney (included on signature page).
|
||
Filing Fee Exhibit
|
ADMA Biologics, Inc.
|
||
(Registrant)
|
||
By:
|
/s/ Brian Lenz
|
|
Name: Brian Lenz
|
||
Title: Executive Vice President and Chief Financial Officer
|
Signature
|
Capacity
|
Date
|
||
|
|
|||
/s/ Adam S. Grossman
|
President and Chief Executive Officer, Director
|
March 7, 2022
|
||
Adam S. Grossman
|
(Principal Executive Officer)
|
|||
|
||||
/s/ Brian Lenz
|
Executive Vice President and Chief Financial Officer
|
March 7, 2022
|
||
Brian Lenz
|
(Principal Financial Officer and Principal Accounting Officer)
|
|||
|
||||
/s/ Steven A. Elms
|
Chairman of the Board of Directors
|
March 7, 2022
|
||
Steven A. Elms
|
||||
|
|
|||
/s/ Dr. Jerrold B. Grossman
|
Vice Chairman of the Board of Directors
|
March 7, 2022
|
||
Dr. Jerrold B. Grossman
|
||||
|
|
|||
/s/ Martha J. Demski
|
Director
|
March 7, 2022
|
||
Martha J. Demski
|
||||
|
|
|||
/s/ Bryant E. Fong
|
Director
|
March 7, 2022
|
||
Bryant E. Fong
|
||||
|
|
|||
/s/ Lawrence P. Guiheen
|
Director
|
March 7, 2022
|
||
Lawrence P. Guiheen
|
||||
/s/ Young T. Kwon
|
Director
|
March 7, 2022
|
||
Young T. Kwon
|
1 Year Adma Biologics Chart |
1 Month Adma Biologics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions